FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to the chemical-pharmaceutical industry and is a method of determining the need of a cancer patient in a combined therapy using a PD-L1 inhibitor – programmed cell death ligand-1, wherein a therapy comprising a modulator of the HER2/neu (ErbB2) signalling pathway and a chemotherapeutic agent, or in which the patient is exposed to a therapy comprising a HER2/neu (ErbB2) signal path modulator and a chemotherapeutic agent; including steps of: measuring in vitro in a sample from the body of said patient levels of expression of the receptor estrogen (ER), PD-L1 and gamma-interferon (IFNγ) and classifying said patient as in need of a combined therapy using a PD-L1 inhibitor, if ER-negative level of expression is established, increased level of expression of PD-L1 in comparison with threshold value PD-L1 and reduced level of IFNγ expression in comparison with IFNγ threshold value. Inventions also include use of Her2/neu (ErbB2) signalling pathway, PD-L1 inhibitor and chemotherapeutic agent, as well as a pharmaceutical composition containing said agents, in treating cancer, wherein for this cancer an ER-negative expression level, an increased level of PD-L1 expression as compared to a PD-L1 threshold value and a reduced level of IFNγ expression in comparison with IFNγ threshold value.
EFFECT: group of inventions enables to determine whether a patient requires a combined therapy using a PD-L1 inhibitor and a modulator of the HER2/neu (ErbB2) signalling pathway for treating cancer.
25 cl, 19 dwg, 6 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
ANTI-PD-L1 ANTIBODIES AND METHODS FOR THEIR DIAGNOSTIC USE | 2015 |
|
RU2715038C2 |
METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO COMPONENTS OF THE SIGNAL PATH PD-1, AND TAXANES | 2014 |
|
RU2719487C2 |
TARGETED/IMMUNOMODULATING FUSION PROTEINS AND METHODS FOR THEIR OBTAINING | 2013 |
|
RU2636342C2 |
METHODS OF TREATING CANCER USING ANTAGONISTS BINDING TO PD-1 AXIS AND TIGIT INHIBITORS | 2014 |
|
RU2702108C2 |
METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND TIGIT INHIBITORS | 2014 |
|
RU2825390C2 |
COMBINATION OF ANTI-PD-L1 ANTIBODY AND DNA-PK INHIBITOR FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2765997C2 |
FGFR2 INHIBITORS SEPARATELY OR IN COMBINATION WITH IMMUNOSTIMULATING AGENTS IN CANCER TREATMENT | 2016 |
|
RU2745707C2 |
VACCINE COMPOSITION AND USE THEREOF | 2016 |
|
RU2726411C2 |
COMBINED THERAPY BASED ON AFUCOSYLATED CD20 ANTIBODY IN COMBINATION WITH CD22 ANTIBODY CONJUGATE - DRUG PREPARATION | 2014 |
|
RU2700092C2 |
COMBINATION OF PD-1 ANTAGONIST AND IDO1 INHIBITOR FOR TREATING ANCER | 2015 |
|
RU2744880C1 |
Authors
Dates
2019-06-27—Published
2013-11-29—Filed